NewLimit

NewLimit is a biotechnology company based in South San Francisco, California, founded in 2021. The company focuses on extending human healthspan by developing epigenetic reprogramming medicines aimed at treating age-related diseases. Their innovative approach involves reprogramming the epigenome to restore youthful function in aged cells without altering cell type. The company is developing therapies targeting specific cell types, starting with hepatocytes to address alcohol-related liver disease. Their technology platform combines functional genomics, machine learning, and high-throughput functional assays to explore the biology of epigenetic aging. NewLimit aims to expand its therapies to other age-associated conditions, inspired by the success of GLP-1 medicines in treating various diseases. With a strong team of experts and significant funding, NewLimit is positioned to lead advancements in aging therapeutics.